Form 10 Explorer
10-K
Annual Report
AIM IMMUNOTECH INC.

AIM

NYSEAMER

CIK: 946644

File #: 001-27072

Period End: Dec 31, 2023

Fiscal Year: 2023

View on EDGAR
Balance Sheet
35 line items · 2 periods
XBRL
ItemDec 31, 2023Dec 31, 2022
ASSETS
Current assets:
Cash and Cash Equivalents
5,439,00027,053,000
Cash and Cash Equivalents
7,631,0007,137,000
Fair Value, Inputs, Level 1
7,631,0007,137,000
Accounts Receivable
1,184,0001,676,000
Other Non-Operating Current Assets
302,000455,000
Total current assets
14,556,00036,321,000
Property, Plant and Equipment
127,000195,000
Operating Lease Right-of-Use Asset
697,000829,000
Intangible Assets
2,313,0001,941,000
Patents
2,197,0001,794,000
Trademarks
116,000147,000
Other Non-Operating Non-Current Assets
1,688,0001,202,000
Total assets
19,381,00040,488,000
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts Payable
6,443,000377,000
Other Current Liabilities
1,986,000806,000
Operating Lease Liability, Current
223,000178,000
Total current liabilities
8,652,0001,361,000
Long-term liability:
Operating Lease Liability, Non-Current
495,000659,000
Total liabilities
9,147,0002,020,000
Stockholders’ equity:
Series B Convertible Preferred Stock
689,000696,000
Total Stockholders' Equity
49,00048,000
Total Stockholders' Equity
419,004,000418,270,000
Total Stockholders' Equity
(409,508,000)(380,546,000)
Total stockholders’ equity
10,234,00038,468,000
Series B Preferred Stock - Common Stock
689,000696,000
Common Stock
49,00048,000
Additional Paid-in Capital
419,004,000418,270,000
Retained Earnings
(409,508,000)(380,546,000)
Total liabilities and stockholders’ equity
19,381,00040,488,000